🔎 Trials Near Me

Home › ALS and Motor Neuron Disease › Maryland

ALS and Motor Neuron Disease clinical trials in Maryland

7 studies for ALS and Motor Neuron Disease are looking for participants at sites in Maryland.

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

  • National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Oct 1, 2026 · NCT07204977

Study of Inherited Neurological Disorders

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 2 to 120 · All sexes · Updated Sep 28, 2026 · NCT00004568

Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers

  • National Institutes of Health Clinical Center, Bethesda
RecruitingHealthy volunteers welcome
Ages 2 to 110 · All sexes · Updated Sep 28, 2026 · NCT01900132

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 17, 2026 · NCT03225144

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · Men · Updated Aug 13, 2026 · NCT04944940

Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth

  • TidalHealth Peninsula Regional, Inc., Salisbury
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 24, 2026 · NCT07491484

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

  • Johns Hopkins Medicine Brain Science Institute, Baltimore
RecruitingPhase 3
Ages 18 to 81 · All sexes · Updated Sep 12, 2025 · NCT03127267

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.